Annual CFO
-$17.14 M
+$915.00 K+5.07%
31 December 2023
Summary:
Fennec Pharmaceuticals annual cash flow from operations is currently -$17.14 million, with the most recent change of +$915.00 thousand (+5.07%) on 31 December 2023. During the last 3 years, it has fallen by -$1.55 million (-9.93%). FENC annual CFO is now -1300.80% below its all-time high of -$1.22 million, reached on 30 June 2000.FENC Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$2.21 M
+$6.18 M+73.70%
30 September 2024
Summary:
Fennec Pharmaceuticals quarterly cash flow from operations is currently -$2.21 million, with the most recent change of +$6.18 million (+73.70%) on 30 September 2024. Over the past year, it has increased by +$554.00 thousand (+20.07%). FENC quarterly CFO is now -105.65% below its all-time high of $39.05 million, reached on 31 March 2024.FENC Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
$23.59 M
+$554.00 K+2.40%
30 September 2024
Summary:
Fennec Pharmaceuticals TTM cash flow from operations is currently $23.59 million, with the most recent change of +$554.00 thousand (+2.40%) on 30 September 2024. Over the past year, it has increased by +$42.68 million (+223.63%). FENC TTM CFO is now -14.14% below its all-time high of $27.48 million, reached on 31 March 2024.FENC TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
FENC Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +5.1% | +20.1% | +223.6% |
| 3 y3 years | -9.9% | +25.4% | +265.4% |
| 5 y5 years | -119.0% | +1.3% | +326.9% |
FENC Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -20.5% | +5.1% | -105.7% | +73.7% | -14.1% | +210.6% |
| 5 y | 5 years | -119.0% | +5.1% | -105.7% | +73.7% | -14.1% | +210.6% |
| alltime | all time | -1300.8% | +5.1% | -105.7% | +73.7% | -14.1% | +210.6% |
Fennec Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$2.21 M(-73.7%) | $23.59 M(+2.4%) |
| June 2024 | - | -$8.39 M(-121.5%) | $23.04 M(-16.2%) |
| Mar 2024 | - | $39.05 M(-903.4%) | $27.48 M(-260.3%) |
| Dec 2023 | -$17.14 M(-5.1%) | -$4.86 M(+76.1%) | -$17.14 M(-10.2%) |
| Sept 2023 | - | -$2.76 M(-30.1%) | -$19.09 M(-10.5%) |
| June 2023 | - | -$3.95 M(-29.2%) | -$21.34 M(+2.7%) |
| Mar 2023 | - | -$5.58 M(-18.0%) | -$20.78 M(+15.1%) |
| Dec 2022 | -$18.06 M(+27.0%) | -$6.80 M(+35.8%) | -$18.06 M(+24.5%) |
| Sept 2022 | - | -$5.01 M(+47.8%) | -$14.50 M(+16.5%) |
| June 2022 | - | -$3.39 M(+18.7%) | -$12.45 M(-7.7%) |
| Mar 2022 | - | -$2.86 M(-12.0%) | -$13.48 M(-5.2%) |
| Dec 2021 | -$14.22 M(-8.8%) | -$3.25 M(+9.7%) | -$14.22 M(-0.3%) |
| Sept 2021 | - | -$2.96 M(-33.2%) | -$14.26 M(-14.9%) |
| June 2021 | - | -$4.43 M(+23.2%) | -$16.75 M(+8.5%) |
| Mar 2021 | - | -$3.59 M(+9.4%) | -$15.44 M(-1.0%) |
| Dec 2020 | -$15.60 M(+72.1%) | -$3.28 M(-39.7%) | -$15.60 M(+12.2%) |
| Sept 2020 | - | -$5.45 M(+74.8%) | -$13.90 M(+30.0%) |
| June 2020 | - | -$3.12 M(-16.9%) | -$10.69 M(+3.5%) |
| Mar 2020 | - | -$3.75 M(+135.8%) | -$10.33 M(+14.0%) |
| Dec 2019 | -$9.06 M(+15.8%) | -$1.59 M(-28.9%) | -$9.06 M(-12.9%) |
| Sept 2019 | - | -$2.23 M(-18.9%) | -$10.40 M(+6.5%) |
| June 2019 | - | -$2.76 M(+11.2%) | -$9.76 M(+13.8%) |
| Mar 2019 | - | -$2.48 M(-15.4%) | -$8.58 M(+9.6%) |
| Dec 2018 | -$7.83 M(+114.9%) | -$2.93 M(+83.2%) | -$7.83 M(+25.9%) |
| Sept 2018 | - | -$1.60 M(+1.8%) | -$6.22 M(+11.5%) |
| June 2018 | - | -$1.57 M(-9.1%) | -$5.58 M(+18.8%) |
| Mar 2018 | - | -$1.73 M(+30.8%) | -$4.69 M(+28.9%) |
| Dec 2017 | -$3.64 M(+71.4%) | -$1.32 M(+37.8%) | -$3.64 M(+24.2%) |
| Sept 2017 | - | -$958.00 K(+39.2%) | -$2.93 M(+16.4%) |
| June 2017 | - | -$688.00 K(+1.9%) | -$2.52 M(+9.5%) |
| Mar 2017 | - | -$675.00 K(+10.5%) | -$2.30 M(+8.3%) |
| Dec 2016 | -$2.12 M(+14.1%) | -$611.00 K(+12.3%) | -$2.12 M(+9.7%) |
| Sept 2016 | - | -$544.00 K(+15.7%) | -$1.94 M(+1.8%) |
| June 2016 | - | -$470.00 K(-5.8%) | -$1.90 M(-2.1%) |
| Mar 2016 | - | -$499.00 K(+17.7%) | -$1.94 M(+4.4%) |
| Dec 2015 | -$1.86 M(+9.6%) | -$424.00 K(-16.7%) | -$1.86 M(-2.3%) |
| Sept 2015 | - | -$509.00 K(-0.4%) | -$1.91 M(+3.6%) |
| June 2015 | - | -$511.00 K(+22.2%) | -$1.84 M(+5.8%) |
| Mar 2015 | - | -$418.00 K(-10.7%) | -$1.74 M(+2.4%) |
| Dec 2014 | -$1.70 M(-23.1%) | -$468.00 K(+5.6%) | -$1.70 M(+1.4%) |
| Sept 2014 | - | -$443.00 K(+8.0%) | -$1.68 M(-1.5%) |
| June 2014 | - | -$410.00 K(+8.5%) | -$1.70 M(-22.0%) |
| Mar 2014 | - | -$378.00 K(-15.1%) | -$2.18 M(-1.3%) |
| Dec 2013 | -$2.21 M(-26.2%) | -$445.00 K(-5.1%) | -$2.21 M(-4.8%) |
| Sept 2013 | - | -$469.00 K(-47.2%) | -$2.32 M(-10.0%) |
| June 2013 | - | -$889.00 K(+118.4%) | -$2.58 M(-8.6%) |
| Mar 2013 | - | -$407.00 K(-26.9%) | -$2.82 M(-5.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2012 | -$2.99 M(-7.2%) | -$557.00 K(-23.3%) | -$2.99 M(-6.6%) |
| Sept 2012 | - | -$726.00 K(-35.9%) | -$3.20 M(+2.9%) |
| June 2012 | - | -$1.13 M(+96.0%) | -$3.11 M(+13.0%) |
| Mar 2012 | - | -$578.00 K(-24.6%) | -$2.76 M(-14.6%) |
| Dec 2011 | -$3.23 M(+67.3%) | -$767.00 K(+20.6%) | -$3.23 M(+3.6%) |
| Sept 2011 | - | -$636.00 K(-17.9%) | -$3.11 M(+2.8%) |
| June 2011 | - | -$775.00 K(-26.0%) | -$3.03 M(+14.7%) |
| Mar 2011 | - | -$1.05 M(+60.0%) | -$2.64 M(+36.9%) |
| Dec 2010 | -$1.93 M(-58.9%) | -$655.00 K(+19.1%) | -$1.93 M(+32.4%) |
| Sept 2010 | - | -$550.00 K(+42.5%) | -$1.46 M(-7.7%) |
| June 2010 | - | -$386.00 K(+14.5%) | -$1.58 M(-42.0%) |
| Mar 2010 | - | -$337.00 K(+84.2%) | -$2.72 M(-41.9%) |
| Dec 2009 | -$4.69 M(-56.6%) | -$183.00 K(-72.8%) | -$4.69 M(-34.2%) |
| Sept 2009 | - | -$672.00 K(-56.1%) | -$7.13 M(-19.7%) |
| June 2009 | - | -$1.53 M(-33.5%) | -$8.87 M(-13.5%) |
| Mar 2009 | - | -$2.30 M(-12.2%) | -$10.26 M(-5.1%) |
| Dec 2008 | -$10.81 M(-18.8%) | -$2.62 M(+8.4%) | -$10.81 M(+4.5%) |
| Sept 2008 | - | -$2.42 M(-17.2%) | -$10.35 M(+2.0%) |
| June 2008 | - | -$2.92 M(+2.5%) | -$10.14 M(+4.3%) |
| Mar 2008 | - | -$2.85 M(+32.0%) | -$9.72 M(-26.9%) |
| Dec 2007 | -$13.30 M(-1.3%) | -$2.16 M(-2.4%) | -$13.30 M(-7.8%) |
| Sept 2007 | - | -$2.21 M(-11.5%) | -$14.43 M(-7.0%) |
| June 2007 | - | -$2.50 M(-61.2%) | -$15.52 M(-7.1%) |
| Mar 2007 | - | -$6.43 M(+95.9%) | -$16.70 M(+23.9%) |
| Dec 2006 | -$13.47 M(+9.9%) | -$3.29 M(-0.5%) | -$13.47 M(-1.4%) |
| Sept 2006 | - | -$3.30 M(-10.3%) | -$13.66 M(-5.2%) |
| June 2006 | - | -$3.68 M(+14.4%) | -$14.42 M(+11.9%) |
| Mar 2006 | - | -$3.21 M(-7.4%) | -$12.89 M(+5.1%) |
| Dec 2005 | -$12.26 M(+104.7%) | -$3.47 M(-14.4%) | -$12.26 M(+39.5%) |
| Sept 2005 | - | -$4.06 M(+89.0%) | -$8.79 M(+25.3%) |
| June 2005 | - | -$2.15 M(-17.0%) | -$7.02 M(+9.7%) |
| Mar 2005 | - | -$2.59 M(+13.3%) | -$6.40 M(-7.9%) |
| Sept 2004 | - | -$2.28 M(+49.5%) | -$6.94 M(+15.9%) |
| June 2004 | -$5.99 M(+16.7%) | -$1.53 M(-14.9%) | -$5.99 M(+5.9%) |
| Mar 2004 | - | -$1.80 M(+34.3%) | -$5.66 M(-0.6%) |
| Dec 2003 | - | -$1.34 M(+0.5%) | -$5.69 M(+0.8%) |
| Sept 2003 | - | -$1.33 M(+11.3%) | -$5.65 M(+10.0%) |
| June 2003 | -$5.13 M(+59.0%) | -$1.20 M(-34.7%) | -$5.13 M(+0.5%) |
| Mar 2003 | - | -$1.83 M(+41.9%) | -$5.11 M(+31.7%) |
| Dec 2002 | - | -$1.29 M(+58.0%) | -$3.88 M(+20.3%) |
| Sept 2002 | - | -$816.30 K(-30.3%) | -$3.22 M(-0.1%) |
| June 2002 | -$3.23 M(+20.1%) | -$1.17 M(+94.7%) | -$3.23 M(+57.0%) |
| Mar 2002 | - | -$601.90 K(-5.1%) | -$2.06 M(+41.4%) |
| Dec 2001 | - | -$634.30 K(-22.7%) | -$1.46 M(+77.3%) |
| Sept 2001 | - | -$821.00 K | -$821.00 K |
| June 2001 | -$2.69 M(+119.7%) | - | - |
| June 2000 | -$1.22 M | - | - |
FAQ
- What is Fennec Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Fennec Pharmaceuticals?
- What is Fennec Pharmaceuticals annual CFO year-on-year change?
- What is Fennec Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Fennec Pharmaceuticals?
- What is Fennec Pharmaceuticals quarterly CFO year-on-year change?
- What is Fennec Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Fennec Pharmaceuticals?
- What is Fennec Pharmaceuticals TTM CFO year-on-year change?
What is Fennec Pharmaceuticals annual cash flow from operations?
The current annual CFO of FENC is -$17.14 M
What is the all time high annual CFO for Fennec Pharmaceuticals?
Fennec Pharmaceuticals all-time high annual cash flow from operations is -$1.22 M
What is Fennec Pharmaceuticals annual CFO year-on-year change?
Over the past year, FENC annual cash flow from operations has changed by +$915.00 K (+5.07%)
What is Fennec Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of FENC is -$2.21 M
What is the all time high quarterly CFO for Fennec Pharmaceuticals?
Fennec Pharmaceuticals all-time high quarterly cash flow from operations is $39.05 M
What is Fennec Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, FENC quarterly cash flow from operations has changed by +$554.00 K (+20.07%)
What is Fennec Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of FENC is $23.59 M
What is the all time high TTM CFO for Fennec Pharmaceuticals?
Fennec Pharmaceuticals all-time high TTM cash flow from operations is $27.48 M
What is Fennec Pharmaceuticals TTM CFO year-on-year change?
Over the past year, FENC TTM cash flow from operations has changed by +$42.68 M (+223.63%)